Table 2.
Clinical details of NSCLC patients with COPD who underwent pulmonary resection after propensity matching
| Characteristics | COPD patients after propensity score matching | |||
|---|---|---|---|---|
| PR (+) | PR (−) | Standardized difference | P | |
| (n = 31) | (n = 31) | |||
| Age (years) | 72.0 ± 8.8 | 71.3 ± 6.5 | 0.090 | 0.695 |
| Gender | ||||
| Male | 27 (87.1) | 27 (87.1) | 0.000 | 1.000 |
| Female | 4 (12.9) | 4 (12.9) | — | — |
| Height (cm) | 161.6 ± 8.1 | 161.8 ± 5.4 | 0.029 | 0.876 |
| Brinkman Index | 986.8 ± 466.3 | 1015.3 ± 820.1 | 0.043 | 0.867 |
| Histology | ||||
| Adenocarcinoma | 19 (61.3) | 19 (61.3) | 0.000 | 1.000 |
| Squamous cell | 10 (32.3) | 10 (32.3) | — | — |
| Others | 2 (6.5) | 2 (6.5) | — | — |
| Tumor size (mm) | 33.6 ± 25.5 | 31.4 ± 17.6 | 0.100 | 0.344 |
| Preoperative pulmonary function | ||||
| VC (mL) | 3332.9 ± 952.8 | 3340.7 ± 620.3 | 0.010 | 0.970 |
| FEV1 (mL) | 1967.1 ± 597.4 | 2063.6 ± 389.9 | 0.191 | 0.455 |
| FEV1% (%) | 61.7 ± 6.7 | 63.9 ± 6.5 | 0.333 | 0.191 |
| %FEV1 (%) | 92.0 ± 16.7 | 97.2 ± 19.0 | 0.290 | 0.257 |
| GOLD | ||||
| 1 | 24 (77.4) | 26 (83.9) | 0.164 | 0.063 |
| 2 | 7 (22.6) | 5 (16.1) | — | — |
| Postoperative predicted value | ||||
| Predicted VC (mL) | 2674.7 ± 908.1 | 2603.7 ± 592.3 | 0.093 | 0.642 |
| Predicted FEV1 (mL) | 1582.7 ± 540.5 | 1604.4 ± 345.3 | 0.048 | 0.850 |
| Predicted %FEV1 (%) | 61.3 ± 13.7 | 62.6 ± 13.2 | 0.097 | 0.635 |
| Performance status | ||||
| 0 | 30 (96.8) | 30 (96.8) | 0.000 | 0.317 |
| 1 | 1 (3.2) | 1 (3.2) | — | — |
| Approach | ||||
| Open thoracotomy | 20 (64.5) | 18 (58.1) | 0.131 | 0.441 |
| VATS | 11 (35.5) | 13 (41.9) | — | — |
| Operation time (minutes) | 214.1 ± 41.1 | 218.4 ± 50.3 | 0.094 | 0.717 |
| Blood loss (mL) | 124.4 ± 96.8 | 110.5 ± 90.8 | 0.148 | 0.560 |
| Pathological staging | ||||
| IA | 7 (22.6) | 8 (25.8) | 0.075 | 0.713 |
| IB | 11 (35.4) | 12 (38.7) | — | — |
| IIA | 5 (16.1) | 4 (12.9) | — | — |
| IIB | 3 (9.7) | 2 (6.5) | — | — |
| IIIA | 5 (16.1) | 5 (16.1) | — | — |
| Post‐operative stay (days) | 16.4 ± 10.3 | 12.1 ± 6.0 | 0.510 | 0.179 |
| Post‐operative complications (%) | ||||
| Total | 2 (6.5) | 5 (16.1) | 0.306 | 0.232 |
| Pulmonary | 1 (3.2) | 3 (9.7) | 0.267 | 0.165 |
COPD, chronic obstructive pulmonary disease; FEV 1, forced expiratory volume in one second; GOLD, Global Initiative for Chronic Obstructive Lung Disease; NSCLC, non‐small cell lung cancer; PR, pulmonary rehabilitation; VATS, video‐assisted thoracoscopic surgery; VC, vital capacity.